| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
139,126,000 |
| Market
Cap: |
128.39(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.9052 - $5.03 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile bluebird bio is a company focused on the pursuit of curative gene therapies for severe genetic diseases. Co. has late-stage clinical and research programs for the treatment of sickle cell disease (SCD), ss-thalassemia and cerebral adrenoleukodystrophy and is developing research to apply new technologies to these and other diseases. Using a proprietary lentiviral vector platform, Co. custom designs each of its therapies to address the underlying cause of disease by introducing a functional copy of a gene to patients' own isolated hematopoietic stem cells. Co. is developing lovotibeglogene autotemcel as a one-time treatment for patients with SCD.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
27,248 |
35,533 |
57,514 |
116,582 |
| Total Sell Value |
$35,492 |
$61,294 |
$139,194 |
$443,003 |
| Total People Sold |
4 |
5 |
5 |
9 |
| Total Sell Transactions |
6 |
9 |
12 |
23 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Wentworth Kory James |
Principal Accounting Officer |
• – – |
2020-07-20 |
4 |
AS |
$66.38 |
$39,562 |
D/D |
(596) |
9,594 |
|
-35% |
|
| Cole Jason |
Chief Operating andLegal Offic |
• – – |
2020-07-02 |
4 |
S |
$61.57 |
$2,340 |
D/D |
(38) |
35,410 |
|
24% |
|
| Gregory Philip D |
Chief Scientific Officer |
• – – |
2020-07-02 |
4 |
S |
$61.57 |
$3,633 |
D/D |
(59) |
36,101 |
|
24% |
|
| Finger Alison Cecily |
Chief Commercial Officer |
• – – |
2020-07-02 |
4 |
S |
$61.57 |
$2,217 |
D/D |
(36) |
27,133 |
|
24% |
|
| Davidson David |
Chief Medical Officer |
• – – |
2020-07-02 |
4 |
S |
$61.57 |
$2,586 |
D/D |
(42) |
39,850 |
|
24% |
|
| Smith-Farrell Joanne |
Chief Business Officer |
• – – |
2020-07-02 |
4 |
S |
$61.57 |
$2,340 |
D/D |
(38) |
22,349 |
|
24% |
|
| Leschly Nick |
President and CEO |
• • – |
2020-07-02 |
4 |
S |
$61.57 |
$27,277 |
D/D |
(443) |
99,904 |
|
24% |
|
| Sellers William R. |
|
– • – |
2020-06-18 |
4 |
A |
$0.00 |
$0 |
D/D |
1,612 |
3,612 |
|
- |
|
| Lynch Daniel |
|
– • – |
2020-06-18 |
4 |
A |
$0.00 |
$0 |
D/D |
2,359 |
7,959 |
|
- |
|
| Dixon Wendy L |
|
– • – |
2020-06-18 |
4 |
A |
$0.00 |
$0 |
D/D |
1,653 |
5,653 |
|
- |
|
| Schenkein David P |
|
– • – |
2020-06-18 |
4 |
A |
$0.00 |
$0 |
D/D |
1,656 |
6,832 |
|
- |
|
| Vachon Mark |
|
– • – |
2020-06-18 |
4 |
A |
$0.00 |
$0 |
D/D |
1,657 |
3,657 |
|
- |
|
| Agwunobi John O |
|
– • – |
2020-06-18 |
4 |
A |
$0.00 |
$0 |
D/D |
1,624 |
6,324 |
|
- |
|
| Melton Douglas |
|
– • – |
2020-06-18 |
4 |
A |
$0.00 |
$0 |
D/D |
1,624 |
6,324 |
|
- |
|
| Wentworth Kory James |
Principal Accounting Officer |
• – – |
2020-06-04 |
4 |
S |
$65.01 |
$10,045 |
D/D |
(154) |
10,190 |
|
17% |
|
| Smith-Farrell Joanne |
Chief Business Officer |
• – – |
2020-06-04 |
4 |
S |
$65.01 |
$11,089 |
D/D |
(170) |
22,387 |
|
17% |
|
| Cole Jason |
Chief Operating andLegal Offic |
• – – |
2020-06-02 |
4 |
S |
$63.36 |
$2,433 |
D/D |
(38) |
35,448 |
|
13% |
|
| Smith-Farrell Joanne |
Chief Business Officer |
• – – |
2020-06-02 |
4 |
S |
$63.36 |
$2,369 |
D/D |
(37) |
22,557 |
|
13% |
|
| Gregory Philip D |
Chief Scientific Officer |
• – – |
2020-06-02 |
4 |
S |
$63.36 |
$3,778 |
D/D |
(59) |
36,160 |
|
13% |
|
| Davidson David |
Chief Medical Officer |
• – – |
2020-06-02 |
4 |
S |
$63.36 |
$2,689 |
D/D |
(42) |
39,892 |
|
13% |
|
| Finger Alison Cecily |
Chief Commercial Officer |
• – – |
2020-06-02 |
4 |
S |
$63.36 |
$2,241 |
D/D |
(35) |
27,169 |
|
13% |
|
| Leschly Nick |
President and CEO |
• • – |
2020-06-02 |
4 |
S |
$63.36 |
$28,433 |
D/D |
(444) |
100,347 |
|
13% |
|
| Smith-Farrell Joanne |
Chief Business Officer |
• – – |
2020-05-04 |
4 |
S |
$49.88 |
$11,639 |
D/D |
(232) |
22,594 |
|
3% |
|
| Leschly Nick |
President and CEO |
• • – |
2020-05-01 |
4 |
A |
$0.00 |
$0 |
D/D |
11,384 |
100,791 |
|
- |
|
| Cole Jason |
Chief Operating andLegal Offic |
• – – |
2020-05-01 |
4 |
A |
$0.00 |
$0 |
D/D |
1,437 |
35,486 |
|
- |
|
939 Records found
|
|
Page 8 of 38 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.01 (1.13%) 
